$AGE News

Last published 2y ago

2y agoAGEAgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial ResultsGlobeNewswireALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating
2y agoAGESerina Therapeutics Announces POZ Polymer Technology License Agreement with PfizerGlobeNewswireProvides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held,
2y agoAGEAgeX Therapeutics Reports Third Quarter 2023 Financial ResultsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September
3y agoACER NXGN SUM AGEMoore Kuehn Encourages AGE, ACER, NXGN, and SUM Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoAGESerina Therapeutics and AgeX Therapeutics Enter into Merger AgreementBusiness WireMerger to result in NYSE American-listed company focused on developing therapeutics based on Serina's proprietary POZ Platform™ delivery technology Lead program of the combined company will be SER-252
3y agoAGEAgeX Therapeutics Reports Second Quarter 2023 Financial ResultsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30,
3y agoAGEAgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred StockBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a
3y agoAGEAgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred StockBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023, AgeX and Juvenescence Limited entered into an Exchange
3y agoAGEAgeX Therapeutics Announces Appeal of NYSE American DeterminationBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17, 2023 it received a notice from the staff of the NYSE
3y agoAGEAgeX Therapeutics Reports First Quarter 2023 Financial ResultsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023. Balance
3y agoAGEAgeX Therapeutics Receives Stock Exchange Deficiency LetterBusiness WireAgeX Therapeutics , Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the "Deficiency Letter") from
3y agoAGEAgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial ResultsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended
3y agoAGEAgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing RequirementsBusiness WireAgeX Therapeutics, Inc. (NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE
4y agoAGEAgeX Therapeutics Reports Second Quarter 2022 Financial ResultsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022. Liquidity and Capital Resources During
4y agoAGEDr. Joanne Hackett Appointed Chairperson of AgeX Board of DirectorsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX's Board of Directors. Dr. Hackett joined the Bo
4y agoAGEAgeX Therapeutics Reports First Quarter 2022 Financial ResultsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022. Liquidity and Capital Resources 2020
4y agoAGEAgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial ResultsBusiness WireSigned research collaboration with University of California, Irvine, on research program for exosome-based therapies for certain brain disorders Licensee ImStem Biotechnology announced first U.S. multiple sclerosis patient dosed with IMS001
4y agoAGEAgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain DisordersBusiness WireResearch to explore therapeutic potential of exosomes and other extracellular vesicles produced by neural stem cells derived from AgeX pluripotent stem cells Research will complement AgeX sponsored program at UCI to develop cell therapies for Hunt
4y agoAGEAgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001Business WireImStem's MSC Product Candidate IMS001 is Derived from AgeX's Pluripotent Stem Cell Line ESI-053 AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced to
4y agoAGEAgeX Therapeutics Receives Stock Exchange Deficiency LetterBusiness WireAgeX Therapeutics , Inc. (NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 17, 2021 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exc
5y agoAGEAgeX Therapeutics Reports Third Quarter 2021 Financial ResultsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2021. Liquidity and Capital Resources A
5y agoAGEAgeX Therapeutics Reports Second Quarter 2021 Financial ResultsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021. Liquidity and Capital Resources As of
5y agoAGEAgeX Therapeutics and LyGenesis Terminate Merger NegotiationsBusiness WireAgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. ("LyGenesis"), a privately held biotechnology company developing cell therapies that enable organ reg
5y agoAGEAgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateBusiness WireSponsored research at The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity Announced Preprint Article Relating to Regeneration, Aging, and Cance
5y agoAGEAgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business UpdateBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and the full year ended December 31, 2020.
5y agoAGEAgeX Announces Preprint Article Relating to Regeneration, Aging, and CancerBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today the online publication of data relating to regeneration, aging, and cancer in bioRxiv. The paper titled “Differential Expression of α, β, and γ Protocadherin Isoforms During Differentiation, Aging, and Cancer” pres ...
5y agoAGEAgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and ObesityBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with The Ohio State University using AgeX’s brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-in ...
5y agoOCX AGELineage Cell Therapeutics Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity OfferingBusiness WireCARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that it raised $11 million in new capital from sales of its holdings of marketable securities, including shares of OncoCyte Corporation (Nasdaq: OCX) and Hadasit Bio-Holdings (TASE: HDS ...
5y agoAGEAgeX Therapeutics and LyGenesis to Negotiate Merger AgreementBusiness WireALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement for a merger of ...
5y agoAGEAgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online OnlyBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held at 10:00 a.m. Pacific Standard Time on Monday, December 28, 2020 will be permitted only through online participation. The County of Alameda, Californ ...
5y agoAGEAgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdateBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, reported financial and operating results for the third quarter ended September 30, 2020.
6y agoAGEAgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress SyndromeBusiness WireALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, and ImStem Biotechnology, Inc. (“ImStem”), a biopharmaceutical company developing embryonic stem cell (ESC) derived mesenchymal stem cells ( ...
6y agoAGELineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic PurposesBusiness WireCARLSBAD, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, ES Cell International Pte Ltd. (ESI), a subsidiary of Lineage, and AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a company focused on developing and commercializing innovative the ...
6y agoAGEAgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic PurposesBusiness WireALAMEDA, Calif. & CARLSBAD, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, and Lineage Cell Therapeutics, Inc. (“Lineage”: NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and ES Cell International ...
6y agoAGEAgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdateBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020.
6y agoAGEAgeX Therapeutics Receives Stock Exchange Deficiency LetterBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in S ...
6y agoAGEAgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDSBusiness WireALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and ImStem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImS ...
6y agoAGEAgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia ABusiness WireALAMEDA, Calif. & LONDON, Ontario--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today a research collaboration where Sernova will utilize AgeX’s UniverCyteTM gene techn ...
6y agoAGEAgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial OfficerBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Andrea Park has been appointed Chief Financial Officer. Ms. Park replaces Russell Skibsted who served in that role since the Company was organized in 2017.
6y agoAGEAgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business UpdateBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the first quarter ended March 31, 2020.
6y agoAGEAgeX Therapeutics Announces Reduction in Projected Cash ExpendituresBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced that based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resu ...
6y agoAGEAgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business UpdateBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and year-end results for 2019.
6y agoAGEAgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple SclerosisBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from human embryonic stem cells has received notificat ...
6y agoAGEAgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian CellsBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a new paper co-authored by two AgeX scientists that could lead to new insights into the fundamental mechanisms of aging and why super-centenarians not only live the longest, but also experience extraordinary h ...
6y agoAGEAgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological DisordersBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a research collaboration with the University of California, Irvine (UCI) using AgeX’s PureStem® technology to derive neural stem cells, with the goal of developing cellular therapies to treat neurological diso ...
6y agoAGEAgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic CellsBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with a Japanese biopharma company utilizing AgeX’s HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells. The research progra ...
6y agoAGEAgeX Therapeutics to Participate at Four Conferences in January 2020Business WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at the following four conferences this month: Biotech Showcase, January 13-15; Precision Medicine World Conference (PMWC 2020), January 21-24; World Stem Cell Summit, Januar ...
7y agoAGEAgeX Therapeutics’ CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in ResearchBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that founder and CEO Michael D. West, Ph.D. will present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, from the Life Extension Advocacy Foundation (LEAF), July 11-12 at The Cooper Union in New York Ci ...
7y agoAGEAgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight InstituteBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, will participate at Biotech Investing in Longevity, an evening event from Aikora Health and Foresight Institute, on Wednesday, May 1, in San Francisco.
7y agoAGEAgeX Therapeutics Receives $4.5 Million From Exercise of WarrantsBusiness WireALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that it has received $4.5 million from the exercise of AgeX common stock warrants. Warrant holders purchased a total of 1,800,000 shares of AgeX common stock through the exercise of warrants at an exercise price of $2.50 ...